Figure 6 (IMAGE) Impact Journals LLC Caption No difference was found in univariate OS analysis for folinic salt use - 37,7 vs 33,4 months - p value 0,151 - maybe due to therapy switch over of a large number of patients who underwent NaLF-based therapy in second line after first-line CaLF-based therapy, partially disguising the overall survival difference between the two groups. Credit Correspondence to - Francesco Jacopo Romano - francesco_jacopo@libero.it Usage Restrictions Copyright: © 2021 Romano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.